ESSA PHARMA INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.585 USD | +2.10% |
|
-6.64% | -16.97% |
| May. 20 | Top Premarket Decliners | MT |
| May. 14 | ESSA Pharma Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 92.65 | 266.4 | 446.3 | 110.9 | 185 | 334.2 | - | - |
| Enterprise Value (EV) 1 | 92.65 | 266.4 | 446.3 | 110.9 | 185 | 334.2 | 334.2 | 334.2 |
| P/E ratio | -2.74 x | -6.93 x | -8.39 x | -2.3 x | -5.15 x | -6.74 x | -5.39 x | -4.06 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | 55 x |
| EV / Revenue | - | - | - | - | - | - | - | 55 x |
| EV / EBITDA | -5,533,500 x | -8,705,617 x | - | - | - | - | - | - |
| EV / FCF | - | - | -13.9 x | -2.97 x | -6.3 x | -6.12 x | -3.02 x | -2.06 x |
| FCF Yield | - | - | -7.2% | -33.7% | -15.9% | -16.3% | -33.1% | -48.6% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 20,762 | 29,009 | 43,984 | 44,073 | 44,101 | 44,363 | - | - |
| Reference price 2 | 4.463 | 9.182 | 10.15 | 2.516 | 4.195 | 7.532 | 7.532 | 7.532 |
| Announcement Date | 12/19/19 | 12/15/20 | 11/18/21 | 12/13/22 | 12/12/23 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | 6.08 |
| EBITDA | -16.74 | -30.6 | - | - | - | - | - | - |
| EBIT 1 | -16.77 | -30.74 | -46.8 | -50.52 | -43.61 | -55.32 | -78.66 | -103.6 |
| Operating Margin | - | - | - | - | - | - | - | -1,703.64% |
| Earnings before Tax (EBT) 1 | -13.66 | -30.22 | -46.42 | -48.13 | -36.07 | -48.54 | -72.83 | -102.8 |
| Net income 1 | -13.71 | -29.85 | -46.37 | -47.98 | -36.08 | -48.54 | -72.83 | -102.8 |
| Net margin | - | - | - | - | - | - | - | -1,690.89% |
| EPS 2 | -1.628 | -1.324 | -1.210 | -1.093 | -0.8143 | -1.118 | -1.396 | -1.855 |
| Free Cash Flow 1 | - | - | -32.11 | -37.35 | -29.36 | -54.6 | -110.6 | -162.4 |
| FCF margin | - | - | - | - | - | - | - | -2,671.39% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 12/19/19 | 12/15/20 | 11/18/21 | 12/13/22 | 12/12/23 | - | - | - |
1CAD in Million2CAD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: September | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 | 2025 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -11.53 | -14.9 | -11.95 | -9.733 | -10.57 | -10.97 | -11.92 | -9.701 | -10.21 | -14.32 | -14.41 | -16.28 | -25.93 | -30.03 | -34.12 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -11.54 | -14.1 | -11.41 | -8.734 | -9.063 | -9.428 | -9.765 | -7.438 | -8.015 | -12.27 | -13.15 | -15.03 | -25.93 | -30.03 | -34.12 |
| Net income 1 | -11.54 | -14.1 | -11.35 | -8.643 | -9.059 | -9.43 | -9.765 | -7.441 | -8.015 | -12.27 | -13.15 | -15.03 | -25.93 | -30.03 | -34.12 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.2665 | -0.3247 | -0.2571 | -0.1914 | -0.2017 | -0.2137 | -0.2274 | -0.1628 | -0.1882 | -0.2730 | -0.3354 | -0.3328 | -0.5730 | -0.6690 | -0.7510 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/3/22 | 5/10/22 | 8/4/22 | 12/13/22 | 2/7/23 | 5/9/23 | 8/8/23 | 12/12/23 | 2/13/24 | 5/14/24 | - | - | - | - | - |
1CAD in Million2CAD
Estimates
Balance Sheet Analysis
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | -32.1 | -37.3 | -29.4 | -54.6 | -111 | -162 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 12/19/19 | 12/15/20 | 11/18/21 | 12/13/22 | 12/12/23 | - | - | - |
1CAD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
7.532
CAD
Average target price
26.67
CAD
Spread / Average Target
+254.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.97% | 243M | |
| +46.77% | 56.87B | |
| +38.65% | 39.72B | |
| -6.51% | 39.27B | |
| -4.42% | 28.73B | |
| +14.20% | 26.21B | |
| -16.81% | 19.79B | |
| +32.14% | 12.28B | |
| +27.46% | 12.23B | |
| -0.52% | 12.12B |
- Stock Market
- Equities
- EPIX Stock
- Financials ESSA Pharma Inc.
